The Phase II trial start for PR013 in Allergic Conjunctivitis follows the recent (5th Dec) start of Phase II trials for PR022 in Atopic Dermatitis, and represents an expected but nevertheless positive development for Realm Therapeutics. In preclinical models, PR013 has demonstrated a significant reduction in itch and a similar reduction in redness vs. high-dose topical steroids. We look forward to top-line results in Q2 2018 and reiterate our positive stance on Realm Therapeutics.
